DESCRIPTION
|
Year of publication : 2021 |
AGS has developed preliminary advice to help clinicians in assisting their patients and surrogates to be fully informed about the risks and benefits of aducanumab based on the available data.
Writing Workgroup
Soo Borson, MD
Peter Hollman, MD, AGSF
Nancy Lundebjerg, MPA
Todd Semla, PharmD, MS, AGSF
Mark Supiano, MD, AGSF
Reviewers
William Lyons, MD, AGSF
Belinda Setters, MD, AGSF
Eric Widera, MD
Final approval
The AGS Executive Committee reviewed and approved this document and made recommendations on behalf of the AGS Board of Directors on July 15, 2021.
DIGITAL :
All UsersFree
You are accessing from
